Skip to main content
Top
Published in: European Journal of Nutrition 8/2019

01-12-2019 | Irritable Bowel Syndrome | Letter to the Editor

Activation of T-regulatory cells by a synbiotic may be important for its anti-inflammatory effect

Authors: Jiezhong Chen, Luis Vitetta

Published in: European Journal of Nutrition | Issue 8/2019

Login to get access

Excerpt

We read with great interest Moser and colleagues’ paper entitled “Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome” published in your journal [1]. The results showed that the synbiotic reduced the symptoms of irritable bowel syndrome (IBS) with increased microbiota diversity and decreased inflammatory status. The synbiotic increased butyrate, a key anti-inflammatory metabolite produced by intestinal commensal bacteria and decreased zonulin, an indicator of intestinal permeability. However, regulatory T-cells (T-Reg cells) changes by the synbiotic were not observed in this study although CD4 T-cells were significantly decreased. As activation of T-Reg cells by butyrate plays a key role in the intestinal inflammatory status [2], it would be interesting to further investigate the reasons as to why they were not altered in this study. We think that this may be related with a pre-existing dysbiosis in IBS; the dysbiotic intestinal microbiota results in reduced efficacious production of butyrate with a concomitant increase in lipopolysaccharide (LPS) translocations from the intestinal lumen to the mucosa. …
Literature
2.
go back to reference Chen J, Vitetta L (2018) Inflammation-modulating effect of butyrate in the prevention of colon cancer by dietary fiber. Clin Colorectal Cancer 17(3):e541–e544CrossRef Chen J, Vitetta L (2018) Inflammation-modulating effect of butyrate in the prevention of colon cancer by dietary fiber. Clin Colorectal Cancer 17(3):e541–e544CrossRef
3.
go back to reference Ford AC, Lacy BE, Talley NJ (2017) Irritable bowel syndrome. N Engl J Med 376(26):2566–2578CrossRef Ford AC, Lacy BE, Talley NJ (2017) Irritable bowel syndrome. N Engl J Med 376(26):2566–2578CrossRef
4.
go back to reference Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J, Storsrud S, Le Neve B, Ohman L, Simren M (2017) Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 152(1):111–123e118CrossRef Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J, Storsrud S, Le Neve B, Ohman L, Simren M (2017) Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 152(1):111–123e118CrossRef
5.
go back to reference Shariati A, Fallah F, Pormohammad A, Taghipour A, Safari H, Chirani AS, Sabour S, Alizadeh-Sani M, Azimi T (2019) The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome. J Cell Physiol 234(6):8550–8569CrossRef Shariati A, Fallah F, Pormohammad A, Taghipour A, Safari H, Chirani AS, Sabour S, Alizadeh-Sani M, Azimi T (2019) The possible role of bacteria, viruses, and parasites in initiation and exacerbation of irritable bowel syndrome. J Cell Physiol 234(6):8550–8569CrossRef
6.
go back to reference Lee MK, Xu S, Fitzpatrick EH, Sharma A, Graves HL, Czerniecki BJ (2013) Inhibition of CD4+ CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine. PLoS One 8(11):e74698CrossRef Lee MK, Xu S, Fitzpatrick EH, Sharma A, Graves HL, Czerniecki BJ (2013) Inhibition of CD4+ CD25+ regulatory T cell function and conversion into Th1-like effectors by a Toll-like receptor-activated dendritic cell vaccine. PLoS One 8(11):e74698CrossRef
7.
go back to reference Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364(1):22–32CrossRef Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364(1):22–32CrossRef
8.
go back to reference Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, Paterson C, Bortey E, Forbes WP (2016) Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 151(6):1113–1121CrossRef Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, Paterson C, Bortey E, Forbes WP (2016) Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 151(6):1113–1121CrossRef
9.
go back to reference Fuke N, Aizawa K, Suganuma H, Takagi T, Naito Y (2017) Effect of combined consumption of Lactobacillus brevis KB290 and beta-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial. Int J Food Sci Nutr 68(8):973–986CrossRef Fuke N, Aizawa K, Suganuma H, Takagi T, Naito Y (2017) Effect of combined consumption of Lactobacillus brevis KB290 and beta-carotene on minor diarrhoea-predominant irritable bowel syndrome-like symptoms in healthy subjects: a randomised, double-blind, placebo-controlled, parallel-group trial. Int J Food Sci Nutr 68(8):973–986CrossRef
Metadata
Title
Activation of T-regulatory cells by a synbiotic may be important for its anti-inflammatory effect
Authors
Jiezhong Chen
Luis Vitetta
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 8/2019
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-019-02080-8

Other articles of this Issue 8/2019

European Journal of Nutrition 8/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.